Peptides: clinics and a compounder sued over CJC-1295, ipamorelin and others being put on a 'significant safety risk' list without advisory review

Source: Evexias Medical Centers et al. v. FDA, No. 4:24-cv-00293 (N.D. Tex., filed Mar. 29, 2024); Alliance for Pharmacy Compounding news, Sept 2024

Before you act: Don't stop, replace, or delay any treatment without talking to your doctor.

““Trust us” is not a sufficient explanation for agency actions.”

Evidence level

Court record (complaint and docket) and trade-association reporting. Allegations, not findings.

Funding

Lawsuit by private clinics/compounder; reporting by a compounding trade group (interested party).

What was published

A suit challenging the 2023 placement of AOD-9604, CJC-1295, ipamorelin acetate and thymosin alpha-1 in Category 2 of the interim compounding bulks list.

What it shows

Plaintiffs argued the peptides were moved without advisory-committee review or notice-and-comment. A settlement led to advisory committee meetings in October and December 2024 to review four peptides.

What it does not show

The suit concerns process, not whether the peptides are safe or effective. BPC-157 was not one of the four peptides challenged.

Documented counterpoints

The trade group says "'Trust us' is not a sufficient explanation for agency actions." The case was administratively closed in Aug 2025 per docket reports.

Source link

Paper Trail Health summarizes published studies, case reports, court filings and journalism for general information. It is not medical, legal or investment advice. Summaries quote the sources; a source's statements are its authors', not findings of this site. Don't stop, replace, or delay treatment without your doctor. Always read the linked original. See Standards & corrections and Disclaimer.